Charles River Laboratories International, Inc. (CRL) is a publicly traded Healthcare sector company. As of May 20, 2026, CRL trades at $156.24 with a market cap of $7.22B and a P/E ratio of -41.91. CRL moved +2.47% today. Year to date, CRL is -25.10%; over the trailing twelve months it is +8.71%. Its 52-week range spans $91.86 to $230.02. Analyst consensus is buy with an average price target of $205.38. Rallies surfaces CRL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who is trading CRL stock inside the company?
Recent CRL insider activity includes LaPlume Joseph W bought 25, LaPlume Joseph W sold 400, LaPlume Joseph W sold 800, LaPlume Joseph W sold 400, and MASSARO GEORGE sold 35. Rallies tracks insider transaction dates, shares, prices, and estimated values.
CRL Key Metrics
Key financial metrics for CRL
Metric
Value
Price
$156.24
Market Cap
$7.22B
P/E Ratio
-41.91
EPS
$-3.70
Dividend Yield
0.00%
52-Week High
$230.02
52-Week Low
$91.86
Volume
747.46K
Avg Volume
0
Revenue (TTM)
$4.03B
Net Income
$-182.84M
Gross Margin
0.00%
Recent CRL Insider Trades
LaPlume Joseph W bought 25 (~$4.36K) on Mar 3, 2026.
LaPlume Joseph W sold 400 (~$65.49K) on Aug 22, 2025.
LaPlume Joseph W sold 800 (~$126.08K) on Aug 18, 2025.
LaPlume Joseph W sold 400 (~$60.02K) on Aug 7, 2025.
Recent CRL insider activity includes LaPlume Joseph W bought 25, LaPlume Joseph W sold 400, LaPlume Joseph W sold 800, LaPlume Joseph W sold 400, and MASSARO GEORGE sold 35. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CRL?
Yes. Rallies tracks CRL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CRL research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CRL. It does not provide personalized investment advice.
